Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2011. The report details a specific share repurchase transaction executed on August 8, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 2,200,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,268 pence per share; lowest price paid was 1,234 pence per share.
- Treasury Holdings: 501,296,816 shares held in Treasury (8.94% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 9.86% of total voting rights.
- Shares in Issue: 5,103,958,123 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 2,200,000 repurchased shares. This action increases the percentage of shares held in Treasury relative to the total issued capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,103,958,123) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 2,200,000 share cancellation on the company's total issued share capital.
- Note that the filing does not contain operational or financial performance data for the period.